A pan‑cancer study using whole‑genome sequencing (WGS) and an HRD classifier found homologous recombination deficiency signatures missed by other assays, detecting HRD across breast, pancreatic, gynecological and prostate tumors; authors urged evaluation of WGS as a clinical diagnostic to broaden PARP inhibitor and platinum therapy selection. Pacific Biosciences announced a collaboration with n‑Lorem and EspeRare to deploy HiFi long‑read whole‑genome sequencing to support individualized antisense oligonucleotide (ASO) therapy design and molecular characterization. PacBio emphasized its role in detailed genome characterization to enable personalized medicine efforts. These items highlight growing clinical use cases for WGS: genome‑wide structural resolution to refine therapeutic eligibility and to power individualized oligonucleotide design—both carry downstream implications for diagnostics, trial enrollment and therapeutic targeting.